Article Information
History
- September 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Institute for Global Health, University College London, London, UK
- 2MRC Clinical Trials Unit, University College London, London, UK
- 3Institute of Immunity and Transplantation, Division of Infection & Immunity, University College London, London UK
- ↵*Correspondence to: Professor David Dunn, MRC Clinical Trials Unit at UCL, 90 High Holborn, London WC1V 6LJ, Tel: (44) 020 7670 4739, e-mail: d.dunn{at}ucl.ac.uk
Posted September 22, 2022.
Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials
